Si Tong, Xing Guoqiang, Han Ying
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
The Affiliated Hospital and the Second Clinical Medical College of North Sichuan Medical University, Nanchong Central Hospital, Nanchong, China.
Front Neurol. 2020 May 19;11:247. doi: 10.3389/fneur.2020.00247. eCollection 2020.
Since late stage dementia, including Alzheimer's disease (AD), cannot be reversed by any available drugs, there is increasing research interest in the preclinical stage of AD, i.e., subjective cognitive decline (SCD). SCD is characterized by self-perceptive cognitive decline but is difficult to detect using objective tests. At SCD stage, the cognitive deficits can be more easily reversed compared to that of mild cognitive impairment (MCI) and AD only if accurate diagnosis of SCD and early intervention can be developed. In this paper, we review the recent progress of SCD research including current assessment tools, biomarkers, neuroimaging, intervention and expected prognosis, and the potential relevance to traumatic brain injury (TBI)-induced cognitive deficits.
由于包括阿尔茨海默病(AD)在内的晚期痴呆无法通过任何现有药物逆转,因此对AD临床前阶段,即主观认知下降(SCD)的研究兴趣与日俱增。SCD的特征是自我感知的认知下降,但难以通过客观测试检测出来。在SCD阶段,相比于轻度认知障碍(MCI)和AD,只有当能够实现SCD的准确诊断和早期干预时,认知缺陷才更容易逆转。在本文中,我们综述了SCD研究的最新进展,包括当前的评估工具、生物标志物、神经影像学、干预措施和预期预后,以及与创伤性脑损伤(TBI)所致认知缺陷的潜在相关性。